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Modulation of cell proliferation by the integrin cytoplasmic domain.
Integrin adhesion receptors modulate cell functions, including cell prolif-
eration and survival. The f3,,- integrin, an alternatively spliced form of /3 IA'
containing a unique cytoplasmic domain sequence, inhibits cell growth in
vitro. In vivo, the expression of f3,c correlates with a benign, nonprolifera-
tive phenotype in epithelial cells. The studies discussed in this article
indicate that modulation of cell proliferation, in normal or pathological
conditions, might be achieved by the regulated expression of variant
integrin subunits.
Integrins
Adhesive contacts between cells and extracellular matrix com-
ponents play a crucial role in organ development, abnormal tissue
growth and tumor progression. These interactions are mediated
by integrins, the most widely distributed gene superfamily of
adhesion receptors, expressed by all mammalian cells [1]. Inte-
grins also mediate cell-cell interactions. The ability to mediate
cell-cell contact, however, is restricted to a few members of the
family (aLl32, aMP2, a132, aD/32, cr4/3, and a4/37) [2—51.
As deduced from immunochemical and molecular evidence,
integrins are structurally organized in heterodimeric transmem-
brane complexes, variously assembled through the non-covalent
association between an a and a )3 subunit [6]. So far, 22 com-
plexes, 16 integrin a subunits and 8 integrin J3 subunits have been
identified and their expression and function characterized in
various cell types [1, 7, 8]. The integrin family is divided in
subfamilies that share the 13 subunit [8]. Each p subunit associates
with one to eight a subunits and each a can associate with more
than one /3 subunit. Function-specificity is determined by the
association of two selected subunits and by the cell type that
expresses the integrin complex [9].
By interacting with both the extracellular matrix and, inside the
cells, with the cytoskeleton, integrins transfer signals from the
extracellular environment to the intracellular compartments and
control many cellular functions, such as growth and migration,
differentiation and gene expression [10]. These signals are initi-
ated after integrin engagement with natural ligands or surrogate
antibody ligands and include increase in cytosolic free [Ca2]1,
tyrosine phosphorylation, elevation of intracellular pH and stim-
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ulated transcription and translation of immediate and early
inflammatory genes [11, 12].
Integrin cytoplasmic domain
Recent experimental evidence obtained with recombinant de-
letion mutants and chimeric forms of the integrin a and 13
cytoplasmic domains, has demonstrated that cytoplasmic tails
modulate ligand binding affinity of the extracellular domain,
receptor distribution, surface expression, cell adhesion and
spreading [6, 7, 13, 14].
Alternatively spliced forms of the a (a1, a6, a7) or /3(13,, /31, /34)
integrin cytoplasmic domains have been identified [1, 6, 15, 16],
thus adding further complexity to the regulatory pathways medi-
ated by integrins.
The integrin J3 subfamily comprises four members: /31 (also
designated I1A), I31B, I3' and /31D [6] that differ in the COOH
terminal sequences as a consequence of alternative splicing events
(Fig. 1). One of these variant forms, designated /3, (formerly f3)
[17], in contrast to other variant /3, subunits [16, 18], is generated
by the presence of an unspliced intervening 116 bp sequence
(Exon C), which causes a frame shift in the wild-type 3' end of the
131A subunit and codes for a unique 48 amino acid COOH-
terminal sequence (Fig. 1). The variant is produced by
retention of an intronic sequence that encodes 12 amino acids.
The /31D results from the insertion of 81 bp exon between Exon 6
and Exon C, resulting in a unique sequence of 24 amino acids.
Exon 7 is not translated in either the /l or the /31D variant and
is partially translated in the j3, variant.
The expression of integrin variants is tissue and cell-type
specific. A selective expression has been shown for the /3
integrin subunit in hematopoietic cells, platelets, activated endo-
thelial cells and in liver, kidney, lung and prostate epithelial cells
[19] (and personal observations). The 131B isoforni has been found
to be mostly restricted to skin and liver tissues [20], while the 131D
subunit has been detected in striated muscles, where it replaces
the common /31A isoform [15, 16, 21]. Similar to /3, variants, a
differential distribution of the following variant forms, 133A, P3,
alA, a6A, a6B a7A and a7 in relationship to their wild-type
counterparts has also been described using protein and mRNA
analysis [6, 15, 16, 21—27].
The cytoplasmic domain of the /31A subunit is highly conserved
from invertebrates to humans [11 and plays a primary regulatory
role in cell migration [22, 281, integrin localization [29, 30], focal
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Fig. 1. Genomic organization and amino acid sequence of the j3 integrin variants. A. The genomic organization of the 13 integrin subunit shows the
presence of four exons encoding four p1 cytoplasmic domains (Exon 6, D, C and 7). Alternatively spliced variants of this subunit share the region
proximal to the membrane in the cytoplasmic domain, through AKWDT, and differ in the COOH-terminal sequence. Unique sequences of respectively
21, 12, 48 and 24 amino acids have been found in the PA. P. P1 and 131D integrin subunits. The drawing was modified from Zhidkova et at, 1995 [151.
B. The cytoplasmic domain sequences of the 131A, PIB, P1 and 11 variant subunits are shown. A comparison with the P3A and P3B spliced variant
cytoplasmic domains is shown.
adhesion kinase (FAK) activation [22, 31—341 and integrin affin-
ities for ligands [35]. Structural changes in the 131A subunit
cytoplasmic domain, due to the presence of the alternatively
spliced sequences, are therefore, likely to generate functionally
different integrin complexes.
The 131D is functionally similar to the I31A variant, since it is
localized at focal contacts, stimulates FAK, and activates mitogen-
activated protein (MAP) kinase [15, 16, 21]. In contrast, the
alternatively spliced integrin 13113 cytoplasmic variant is not
localized at focal contacts and inhibits cell adhesion and
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Fig. 2. Expression of in prostate epithelial cells. (A, B) Sections, from a formalin-fixed and paraffin-embedded needle biopsy specimen of benign
hyperplastic prostate tissue, were evaluated by immunoperoxidase staining performed using 3.75 j.rg/ml affinity purified antibodies to PR 785 to 808 (A)
or non-immune control lgG (B). Glandular epithelial cells, hut not basal cells, positively reacted with the antibodies to I3c 785 to 808. Magnification
was X400 (A, B). C. Reverse transcription (RT) and PCR analysis were used to study /3 RNA expression. Total RNA (8 ,xg) was transcribed using
200 units per reaction of Superscript II RNase H-- Reverse Transcriptase and 5 xg/m1 random primers. PCR was performed using two amplifi-
cation steps. One-tenth of the eDNA from reverse transcription was used in the first round of PCR. Primers from sequences common to f3 and p1
[2260—2280 from the published sequences of both PIA and j3 [171 and 2476-2497 from the PA sequence or 2592-2613 from the Pc sequence, where
underlined positions indicate the 5' nucleotide) were used in the first amplification of all cDNAs. One-twentieth of the PCR product from the first
amplification was used for the second amplification. Primers specific for were used in lanes 2,3, and 4 [,—2448, including a BamHl restriction
site and 2569-2581, including an EcoRI restriction site; predicted fragment size except for control lane: 162 bp] and primers common to and PA
were used in lanes 5, 6, and 7 to amplify PIA [2309—2329 and 2453-2465, including an EcoRI restriction Site on the 3' end; predicted fragment size except
for control lane, 164 bpl. Both rounds of PCR amplification were performed using I unit Vent polymerase, 100 /.LM each dATP, dCTP, dGTP, dT'FP,
0.1 jxM forward and reverse primers. PCR was carried out in a DNA Thermal Cycler under the following conditions: denaturation at 95°C for one
minute, annealing at 45°C for one minute, extension at 72°C for one minute. Thirty cycles of amplification were performed. The PCR products for
lanes 2 and 3, and PA, lanes Sand 6, were from normal prostate tissue, lanes 2 and 5, or from a prostate cell line, lanes 3 and 6. Lanes 4 and 7, negative
control cDNAs. DNA markers were Lane 1, 100 bp ladder; Lane 8, 4X174/HaeIll fragment markers.
motility [22]. This suggests that modulation of splicing patterns of
1 mRNAs may provide an accessory mechanism to regulate
signaling pathways that are initiated by integrins.
Integrins modulate cell growth and survival
Signal transduction by integrins includes activation of pathways
that control cell growth and survival [36—39]. Cell adhesion and
spreading on fibronectin, vitronectin and collagen activates MAP
kinase [40, 41] and Ras-independent and dependent pathways
have been implicated in MAP kinase activation by integrins [42,
43]. Cell adhesion mediated by integrins modulates the cell cycle,
whereas detachment from the matrix induces apoptosis and
causes arrest of the cell cycle [44—47]. The latter effect has been
demonstrated to be dependent on increased expression of two
cyclin-dependent kinase inhibitors, p2lC and p27'"'1, a mech-
anism that resembles the cell cycle arrest induced by TGF-p in
epithelial cells [47]. Cyclin A and cyclin E-dependent kinase
activity are also known to be induced by cell attachment to the
matrix, strongly supporting the evidence that complex pathways of
growth control are mediated by integrins and their ligands [40,
46—50]. Integrin ligation contributes to the proliferation of trans-
formed cells [51] and in the absence of the ligand, integrins block
cell proliferation and down-regulate c-fos and c-jun early genes.
The mechanisms of signaling that occur proximal to the mem-
brane are poorly known; integrin clustering or association with
members of the transmembrane-4-superfamily might be ways to
trigger proliferation signals and consequently, regulate tumor
growth [36, 52].
Several studies have implicated FAK, a substrate for src, as a
key player in integrin signaling [53]. FAK is activated by integrin
engagement, and its activation is accompanied by anchorage-
independent growth and significant tumorigenic potential [54].
FAK hinds to paxillin, p1 30s, phosphatidylinositol-3 kinase, c-src
and Grb2; the last one forms complexes with SOS, that can
ultimately activate ras [53]. FAK is also activated by mitogens, like
platelet derived growth factor suggesting a role in mediating
synergistic effects of integrins and growth factors [55]. Further
investigations will be necessary to determine the role of FAK in
regulating the sequence of downstream signaling events triggered
by integrin-ligand interactions.
I3, integrin inhibits cell proliferation
A role for p integrin and its cytoplasmic domain in the control
of cell proliferation and differentiation has been demonstrated
[56—59]. Ligation of I3 integrins prevents apoptosis [45, 57] and
increases cell growth and survival of normal human breast epithe-
hal cells [58]. Furthermore, a role for the p1 integrin cytoplasmic
domain in the control of cell proliferation has been shown by
Pasqualini and Hemler [59]. Selective expression of the 131A and
not of a chimeric form containing the 13 cytoplasmic domain,
augments fibronectin-dependent proliferation of transfected
CHO cells in the presence of an integrin-activating antibody [59].
Such growth regulatory mechanisms are not exclusively restricted
to the /31 integrin. Along the same line, the cytoplasmic domain of
an integrin that is de novo synthesized in squamous cell
1436 Zheng ci al: f3, integrins and cell proliferation
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Fig. 3. Down-regulation of f3 in cancer.
Neoplastic prostate tissue sections were stained
using affinity-purified antibodies to 13, 785 to
808 peptide (5 .cgIml, A), to PIA 765 to 798
peptide, (2 p.g/ml, C) or non-immune rabbit
IgG (5 jsg/ml, B, and 2 .xg/ml, D). The
magnification was X200 for all panels. In
adjacent areas of the same section, benign
glands were 131ç-positive (not shown and [19]).
carcinoma [601, plays a positive role in up-regulating DNA
synthesis and proliferation of colon carcinoma cells [611.
Recent studies have identified a unique function of in the
regulation of cell growth [50, 62]. Expression of human recombi-
nant f3,. in CHO cells or C3H IOT1/2 fibroblasts inhibits DNA
synthesis and cell proliferation, whereas the P[A did not. The
effect of Pie expression on cell proliferation is not associated with
changes in exposure of integrin functional epitopes, as judged by
the finding that CHO transfectants expressing f31, full length or
deletion mutants, or PtA equally adhered to a functionally inhib-
itory monoclonal antibody against human 13 integrin.
Residues G1n795-Gln802 of the variant cytoplasmic domain show
a role in mediating /3k. effect on cell proliferation [62]. Although
we might speculate that the Gln795-0ln802 region may play a direct
role in the interaction with as yet unidentified intracellular
ligand(s), other mechanisms, including secondary structure and
conformational remodeling, cannot be presently excluded. A role
for f3- in negatively regulating cell cycle progression in late G,
has been highlighted in non-tumorigenic 1OTI/2 fibroblasts upon
f3 eDNA microinjection [50]. In this study, using a different cell
type and experimental system, a role for only the extreme 13
carboxy-terminal amino acids of 13was shown in the inhibitory
effect of cell cycle progression. This difference may be a conse-
quence of the non-tumorigenic as opposed to the tumorigenic cell
phenotypes used in the two studies. However, the contribution of
a unique integrin cx subunit in either cell type in determining the
role of the different f3. cytoplasmic regions in regulating cell
growth cannot be presently excluded. The overall results allow us
to speculate that the intracellular mechanisms that mediate f3.
effect are multiple and diverse in different cell types.
Absent on growing cultured endothelial cells, surface expres-
sion of f3 is induced in growth-arrested, tumor necrosis factor-
stimulated endothelial cells [62]. These findings suggest that
integrin alternative splicing may provide an accessory mechanism
to modulate cell type-specific growth regulatory pathways during
vascular cell injury and cytokine-dependent inflammation in vivo.
IJ integrin is down-regulated in cancer
Additional evidence regarding the role of integrins and their
ligands in cell growth derives from studies performed on cancer
cells. At the molecular level, it has been demonstrated that
genetically engineered transfectants expressing 13 integrins play
either a positive [63] or negative [64, 65] role on tumor cell growth
or metastatic dissemination in vivo. Immunohistochemical or
biochemical studies have demonstrated that integrin expression is
differentially regulated in neoplasia [66—68] and that alteration of
integrin expression in cancer cells correlates with increased inva-
siveness, tumor progression and metastatic potential in vivo and in
vitro [69]. The use of integrin antagonists in in vivo animal models
has revealed that integrins modulate angiogenesis and regulate
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certain aspects of programmed cell death, thus directly influenc-
ing the tumor growth potential and metastatic dissemination of
malignant cells [70, 711.
The potential role of 13 integrin in cancer growth has been
previously investigated [19]. In benign and neoplastic human
prostate tissues, immunohistochemical and immunoblotting anal-
ysis (Figs. 2 and 3) [19] performed using affinity-purified antibod-
ies specific for demonstrates a predominant epithelial expres-
sion of I3ic in benign prostate glands with marked staining of the
apical, basal and lateral surfaces. In prostate adenocarcinoma
glands, the 13 variant is dramatically down-regulated in 27 out of
34 (79%) analyzed cases, whereas the expression and distribution
of its wild-type counterpart, 13 IA' remains unchanged (Fig. 3). The
13 reactivity is down-regulated in comparison to the benign
tissue regardless of the histological grade. Taken together, these
data show that p integrin down-regulation in prostate tissues
correlates with a neoplastic phenotype consistent with its in vitro
growth inhibitory properties, suggesting that the i31-mediated
intracellular signaling pathways are likely to play a crucial role in
the modulation of prostate cell growth.
Previous studies by several investigators have demonstrated
that malignant transformation and invasiveness of epithelial pros-
tate cells is associated with changes in integrin distribution, in cell
lines in vitro [72—74], but also in vivo [75—771. Similarly, altered
expression of integrins in epithelial cells generates phenotypes
that show abnormal proliferation. In normal skin, the 13 integrins
are found only in the basal layer of the epidermis, while during
wound healing and psoriasis, which are associated with hyperpro-
liferation, they also appear in the suprabasal layers of the skin [78,
79]. Specifically, abnormal expression of the 131 integrin in the skin
suprabasal epidermal layers in transgenic mice caused epidermal
hyperproliferation. Taken together, these studies indicate that
incorrect integrin distribution might be a trigger for in vivo
changes in cell growth rate.
Conclusions
While a differential modulation of cellular function (migration,
FAK activation, adhesion to the substrate) mediated by 13 IA' I3IB,
133A' 133B, aCA, a has been shown and is suggestive of new
pathophysiological implications for integrin splicing [22, 28, 33,
80], the ability to inhibit cell proliferation remains a unique
feature of the 13 isoform. Through its unique cytoplasmic
sequence, 13 may act as a novel and regulated "growth suppres-
sor" cellular component.
The dynamic regulation by alternative mRNA splicing and its
cell growth inhibitory potential make the PlC variant an ideal
model to elucidate the sequence of events between integrins and
intracellular signaling mechanisms that affect cellular functions.
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